Please login to the form below
Trajenta
This page shows the latest Trajenta news and features for those working in and with pharma, biotech and healthcare.
Boehringer bolsters NASH pipeline with $870m Yuhan deal
Boehringer already has an existing relationship with Yuhan, which acts as the South Korean marketer for three of the German firm’s Eli Lilly-partnered diabetes therapies, Tradjenta (linagliptin), Trajenta Duo
Latest news
-
Boehringer Ingelheim calls for "strong and united" Europe
In particular, Eli Lilly-partnered diabetes franchise based on DPP-4 inhibitor Trajenta (linagliptin) climbed 23% to 1.1bn while sales of lung disease therapy Ofev (nintedanib) more than doubled to
-
The Global Awards 2016 finalists announced
Sudler &Hennessey London's diabetes iPad game, 'The Journey Ahead Challenge' for Trajenta EASD Congress Activity also made the cut. ... The campaign saw players earn 'fuel' in the driving game by answering questions about diabetes and Trajenta's brand.
-
Boehringer Ingelheim returns to growth after US turnaround
Sales of DPP-4 inhibitor Trajenta (linagliptin) and its Jentadueto (linagliptin and metformin) combination rose 42.9% to 909m. ... The company will not publish separate sales figures for Trajenta and Jentadueto until next year, but said 2015's
-
Langland and CAHG take top prizes at Best of Health Awards
Healthcare Professional - Digital Media. 'The Road Ahead Challenge' for Trajenta, by Sudler London .
-
Boehringer returns to growth in first half
1% increase to reach 5.4bn thanks to higher sales of its Trajenta (linagliptin) franchise. ... Trajenta and combination product Jentadueto (linagliptin and metformin) climbed 22% to 419m in the six-month period, although this growth rate is well below
Boehringer Ingelheim calls for "strong and united" Europe
The Global Awards 2016 finalists announced
Boehringer Ingelheim returns to growth after US turnaround
Langland and CAHG take top prizes at Best of Health Awards
Boehringer returns to growth in first half
More from news
Approximately 1 fully matching, plus 25 partially matching documents found.
Latest Intelligence
-
Market dynamics, marketing and analytics
Secondly, growth is ebbing away from Forxiga (dapagliflozin), the first entrant of the DPP4s, which is actually growing slightly slower than Trajenta. ... The key points here are that Trajenta is used by just under 8, 000 practices but appears to have
-
Interview: Beate Wieseler, IQWIG
This includes Germany-based Boehringer Ingelheim's disapproval of the generic comparator used in IQWiG's AMNOG assessment of the diabetes medicine Trajenta (linagliptin).
-
Interview: Allan Hillgrove, Boehringer
The launch of Trajenta has been positive in many markets around the world. ... reimbursement body IQWIG refusing to recommend several new drugs, including Boehringer's diabetes treatment Trajenta.
-
A new dogma in HTA assessment
Ingelheim and Eli Lilly's Type 2 diabetes drug Trajenta (linagliptin).
-
Country report: The healthcare market in Germany
6. Less than comparator. It is significant that last year, BI and Lilly decided not to launch their new diabetes drug Trajenta in Germany, blaming price controls. ... Out of the 10 products assessed last year, four have obtained poor innovation scores:
Market dynamics, marketing and analytics
Interview: Beate Wieseler, IQWIG
Interview: Allan Hillgrove, Boehringer
A new dogma in HTA assessment
Country report: The healthcare market in Germany
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Medical Editor
-
Competitive Salary
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
-
Senior Medical Writer
-
Competitive Salary
-
Senior Account Executive
-
Competitive Salary
-
Publications Director
-
Competitive Salary
-
Account Management
-
Competitive Salary Offered
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
-
Account Manager
-
Competitive Salary
-
Associate Account Director
-
Competitive Salary
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Positive results for GSK/CureVac’s COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- Biogen and Capsigen to collaborate on gene therapies
- CanSinoBIO considers booster jab for COVID-19 vaccine
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- Merck & Co reveals plans for women’s health spinoff Organon
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Why female mentorship is so powerful in pharma
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Can protein degraders unlock ‘undruggable’ drug targets?
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
